Royalty Pharma Fair Value
RP
The fair market value of RPRX stock is 75.41 USD. Relative to the market price of 25.995 USD Royalty Pharma is undervalued by 189.8%
Eyestock's quantitative valuation approach is based on the method of estimating historical multipliers. To determine whether a stock is undervalued, we compare its current price to our estimated of fair value. The more undervalued a stock is, the more investment is profitable.
Fair Relative Value
Royalty Pharma Valuation
Current RPRX share ticker price is 25.995 USD.
The fair value level of 75.41 USD can be considered as an effective entry point for long-term investors to start investing in RPRX stock. For a more in-depth assessment, we provide a minimum value that can be used to increase a stock position and a maximum one that can be used to reduce it.
Price chart is not available
Current market price
Current price is 190% lower its fair value
Current price is 39% lower its minimum value
Current price is 497% lower its maximum value
Market price:
RPRX stock is greatly undervalued
It means the current price may concern as a Low Risk Entry Point
Royalty Pharma PLC Stock Valuation Calculator
How do we value a stock?
As fair value, we use the product of the median Price-to-earnings ratios at the end of each reporting period for the last 5 years and earnings per share for the last 12 months. By analogy with the fair value, we calculate the maximum and minimum ones using the corresponding P/E extremums.
1
Maximum P/E over 5 years
80.88
2
Median P/E over 5 years
39.27
3
Minimum P/E over 5 years
18.77
4
Earning per share (last 12 months)
1.92 USD
Maximum value
1
x
4
=
155.32 USD
Fair value
2
x
4
=
75.41 USD
Minimum value
3
x
4
=
36.05 USD
Royalty Pharma PLC price metrics
-11.69
Annual return (geometric mean)
27.74
Risk (standard deviation) of returns
β
0.45
Beta (volatility compared to market)